Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG oligodeoxynucleotide + aluminum hydroxide
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Inorganic Nanoparticles → Nanoparticles → Drug Delivery Systems, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intradermal, Intraperitoneal
01
Overview
CpG oligodeoxynucleotide + aluminum hydroxide is a **combination vaccine adjuvant** comprising synthetic unmethylated CpG motifs (CpG-ODNs) and aluminum hydroxide (commonly referred to as alum). CpG-ODNs are short, synthetic single-stranded DNA sequences that mimic bacterial DNA, acting as potent **Toll-like receptor 9 (TLR9) agonists**. This combination stimulates the innate immune system by activating antigen-presenting cells (APCs) and B cells, driving a Th1-skewed immune response and promoting the production of neutralizing antibodies and regulatory cytokines[1][2][3][4]. Aluminum hydroxide acts both as a classic depot adjuvant, enhancing antigen retention and presentation, and as a co-adsorbent to CpG-ODNs, optimizing co-delivery and efficacy[1][4]. Used in candidate and investigational vaccines (e.g., SARS-CoV-2, pertussis, malaria), this adjuvant pairing has demonstrated increased immunogenicity versus either adjuvant alone[1][3][4].
- Other names
- CpG-ODN + alumCpG ODN + aluminum hydroxideCpG adjuvant + alumCpG 7909 + aluminum hydroxideCpG 1018 + alum
02
Targets
TLR9 (Toll-like receptor 9)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on CpG oligodeoxynucleotide + aluminum hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG oligodeoxynucleotide + aluminum hydroxide.